Kovač, MD, PhD, Viljem, et al. “Intercalated Chemotherapy and Erlotinib for Advanced NSCLC: High Proportion of Complete Remissions and Prolonged Progression-Free Survival Among Patients With EGFR Activating Mutations”. Radiology and Oncology, vol. 48, no. 4, Oct. 2014, https://radioloncol.com/index.php/ro/article/view/2233.